p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. - Test2 - elhamkhani - TriplyDB

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

http://www.wikidata.org/entity/Q27851827

about

Smoking, p53 mutation, and lung cancer Therapeutic targeting of replicative immortality Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition.CIViC database The rebel angel: mutant p53 as the driving oncogene in breast cancer.Small molecule compounds that induce cellular senescence Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Chemosensitivity and p53; new tricks by an old dog Poor survival with wild-type TP53 ovarian cancer?Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells p53 is a key regulator for osthole-triggered cancer pathogenesis.A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer.Doxorubicin, DNA torsion, and chromatin dynamics.p53 Family and Cellular Stress Responses in Cancer.Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining.Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer.Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions.IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.Wild type p53 reactivation: from lab bench to clinic.Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo.p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells Che-ating death: CHE1/AATF protects from p53-mediated apoptosis.A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line.Recent discoveries in the cycling, growing and aging of the p53 field Nucleolar repression facilitates initiation and maintenance of senescence.Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma Prognostic significance of p53 immunoexpression in the survival of oral squamous cell carcinoma patients treated with surgery and neoadjuvant chemotherapy.TP53 drives invasion through expression of its Δ133p53β variant.

P2860

26b628bd271b5ccbcd8c001cf45515fa6bd45562 8249fc77bd51ef94ff54a41ca2a6905de1e04dde

P248

Q27014977-FF732771-C290-4811-BDD1-1060776D413C Q27027457-04714751-1D00-4248-B4F3-9A9DE85E73A8 Q27306356-D5F66060-1CFA-4CFC-85E6-0417ACFE86A4 Q27612411-4B456D8E-A27E-4FBA-A893-D58E25DC212B Q27686765-BA3F7273-00F9-41D9-BB42-DF859F2104D8 Q28068732-99C4C5E5-DC0A-4B9A-96D4-F4BFFA43A842 Q28468360-9ED0EC4A-ABE5-479B-9C50-204460789F10 Q30313610-4A9FD211-395A-47A3-BB8D-E0B0CC4DD689 Q30366115-8CD53BAA-BD7A-47C1-B99A-CB247B75B465 Q30543788-C2371077-4800-43FC-AFBA-3EB7949BBCCD Q33572016-FACCCA48-AD0B-4098-91B6-93CDA3C91FC7 Q33739325-4D170263-653A-4E23-B2A9-155F2180CF6E Q33761535-EB377685-A1E8-477E-8E69-4FFB7F17412D Q33812688-39210A6F-0AD7-4FED-8865-76D1371B5C1B Q33821688-BB399BDE-877F-4034-9FD1-DFB8BE6918DF Q33835581-F3262FBF-B5DA-4DA3-9333-EB396A28C286 Q34039414-DA464E7A-7A1E-48F1-B155-75C0694EB9A4 Q34377287-60F2771B-0585-45F8-BA05-A1BB87147414 Q34491545-9D9FBE19-F178-4F3C-9BDA-ADECE73393DB Q34533669-093AE15A-B7A2-4437-966E-57306859DBAF Q34566248-490E9CBF-D5FC-46C6-9F88-3AB1679CB705 Q34810055-682A4408-5AC5-4503-9DAB-A3B12A472261 Q34961997-785E388C-22A1-4D94-93B7-6E56703D4EFA Q35032609-93716DD8-9166-44EC-A47E-19C602EBBBC3 Q35146343-5097F107-1E89-42FE-A8DC-A19808378D88 Q35349417-709C78CF-C908-4270-8CB7-CF6C3A689D67 Q35587605-72ECF5C4-C1AF-4035-9AA6-244F6A7F883A Q35619493-BFE1BCC0-A2CE-4D10-8273-A955A661820A Q35740145-61720AE3-E433-4A7F-AED7-3F4E5581EAFE Q36234051-E6D43C7C-A749-4982-AA85-2154317D1837 Q36328705-87EC80C0-014F-4FB5-869F-3B23631B9AAA Q36545528-87281D65-86D8-48DF-8D4F-5B75F7447FC5 Q36602188-5C96BB2F-5738-4C2A-8044-E8C00F7A9905 Q36614217-559D9182-538E-45D3-8B04-93B5EF96F097 Q36736358-D427520A-F311-4965-BDC2-CC9EB8F6C11C Q36781105-E340E016-AF7A-4869-9C93-E695945E8CDE Q36905671-C3F612E3-7318-40C8-860A-6B34B34A33A1 Q37179323-296699B1-39ED-4E2B-810A-09232A2D057D Q37326095-7C3EAD54-B84F-4A8A-9A54-C9BC00CE496E Q37344716-1514446E-B691-4652-8465-62D5D952F8BB

P2860

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

http://www.wikidata.org/entity/Q27851827

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

p53-mediated senescence impair ...... ical outcome in breast cancer.

@ast

p53-mediated senescence impair ...... ical outcome in breast cancer.

@en

p53-mediated senescence impair ...... ical outcome in breast cancer.

@nl

type

label

p53-mediated senescence impair ...... ical outcome in breast cancer.

@ast

p53-mediated senescence impair ...... ical outcome in breast cancer.

@en

p53-mediated senescence impair ...... ical outcome in breast cancer.

@nl

altLabel

p53-Mediated Senescence Impair ...... nical Outcome in Breast Cancer

@en

prefLabel

p53-mediated senescence impair ...... ical outcome in breast cancer.

@ast

p53-mediated senescence impair ...... ical outcome in breast cancer.

@en

p53-mediated senescence impair ...... ical outcome in breast cancer.

@nl

P1433

Q27851827-324029D8-9B83-4A7C-869B-5AEFFAEB211E

P1476

Q27851827-8B9FE470-AAD9-41B3-9690-8BA07269D3C4

P2093

Q27851827-28365AEE-B18D-440F-B38A-5D59C533187B

Q27851827-2C39982B-5EA1-45B7-825F-7AC0D6263E73

Q27851827-2F73FFC6-D329-469B-9FE1-4B2BFB46A4BA

Q27851827-31F8BDE9-FA8D-4EC9-966E-1789AC981D1D

Q27851827-5D70F96A-44E1-454D-A006-1061275759EA

Q27851827-6594EA05-DACC-4A0B-B1D4-F0A11B3A5117

Q27851827-7310F0A5-254D-4CD5-B2BD-4F7E2416B938

Q27851827-8C63F69B-8F5F-4292-8BD3-121DBE46C16E

Q27851827-A6D4B9AF-BFF6-4736-A4D5-55EB5C7FC026

Q27851827-C9696A95-A2F2-4C1A-B451-91C67B5FAC64

P2860

Q27851827-02DD9A9E-4627-4FED-B7DC-992D2A904F76

Q27851827-0340D63B-21CB-4363-97F3-1E199F8D2E26

Q27851827-0CE66732-7AAE-48A8-985C-C07F9F842A12

Q27851827-0F090776-0C7C-49DE-AF09-6FE679DD45BB

Q27851827-0F2AA4BC-7659-4514-88DC-42C00BF5D5EB

Q27851827-152A72E4-37A0-4EA4-B7F7-DF5F9AFA09B0

Q27851827-17B87DC2-06BD-453B-8B11-C0033DECD64A

Q27851827-1EDA47C7-667A-4BD4-9A88-5CFEBDE6D79B

Q27851827-21B8D01D-16C1-45EC-B879-539F679D0A3F

Q27851827-29C03D97-400D-4775-BB17-FC4B5193EE0A

P304

Q27851827-FCB7B0B2-4552-4DBF-934E-1D9408845360

P31

Q27851827-F93938D9-8589-4556-9AAE-CA64A458FB72

P3181

Q27851827-0C8B0156-08D7-4E27-B8B7-0091700D7757

P356

Q27851827-CEB543A2-79D0-4A2B-BCC3-943E7E96EC3E

P433

Q27851827-4C621667-C266-49AD-A0B8-6FB3B8E28490

P478

Q27851827-D57DE07A-B5B8-4B03-9342-93856FBAB691

P50

Q27851827-4BF415A9-2E00-459F-9F5A-81484B4C4887

P577

Q27851827-66EE498A-D7F5-42A4-B4C1-793A7A8E8ABD

P5875

Q27851827-7EEFC49E-2EF4-43A9-9385-C769E62DFB6D

P698

Q27851827-21F597C9-1276-47C5-BA1F-9F1B9B42FCB2

P921

Q27851827-1C2E24FA-C0EB-48A7-9225-B6260133A87F

Q27851827-2E79B8D8-4365-46C7-BAF9-1F415E23D317

Q27851827-3CD9D0DD-300D-47B1-BD74-2D4EC73943E0

P932

Q27851827-C800F486-49F8-45F3-B593-0B291396AB3E

P3181

P356

J.CCR.2012.04.027

P1433

P1476

p53-mediated senescence impair ...... nical outcome in breast cancer

@en

P2093

Adel K El-Naggar

http://www.w3.org/2001/XMLSchema#string

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

Daniel Garza

http://www.w3.org/2001/XMLSchema#string

Guillermina Lozano

http://www.w3.org/2001/XMLSchema#string

Leslie L Chang

http://www.w3.org/2001/XMLSchema#string

Omid Tavana

http://www.w3.org/2001/XMLSchema#string

Peirong Yang

http://www.w3.org/2001/XMLSchema#string

Qin Li

http://www.w3.org/2001/XMLSchema#string

Taghi Manshouri

http://www.w3.org/2001/XMLSchema#string

Vinod Pant

http://www.w3.org/2001/XMLSchema#string

P2860

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

A biomarker that identifies senescent human cells in culture and in aging skin in vivo

Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network.

Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1

Chemokine signaling via the CXCR2 receptor reinforces senescence

p21 is necessary for the p53-mediated G1 arrest in human cancer cells

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor

P304

793-806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3520635

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CCR.2012.04.027

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

James G Jackson

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225373297

http://www.w3.org/2001/XMLSchema#string

P698

22698404

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

3376352

http://www.w3.org/2001/XMLSchema#string